Profile data is unavailable for this security.
About the company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
- Revenue in EUR (TTM)776.60m
- Net income in EUR-90.69m
- Incorporated2019
- Employees5.06k
- LocationEvotec SEEssener Bogen 7HAMBURG 22419GermanyDEU
- Phone+49 40560810
- Fax+49 4 056081222
- Websitehttps://www.evotec.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 114.85m | -45.98m | 1.09bn | 219.00 | -- | 93.00 | -- | 9.46 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| BioGaia AB | 113.93m | 32.52m | 1.09bn | 211.00 | 34.76 | 5.95 | 31.41 | 9.56 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Polypeptide Group AG | 324.72m | -51.42m | 1.13bn | 1.20k | -- | 2.95 | -- | 3.48 | -1.52 | -1.52 | 9.59 | 11.31 | 0.5137 | 2.31 | 5.08 | 264,248.20 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| AddLife AB | 858.34m | 6.92m | 1.18bn | 2.29k | 176.46 | 2.70 | 13.24 | 1.38 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| FAES Farma SA | 463.85m | 94.75m | 1.20bn | 1.75k | 12.41 | -- | 10.52 | 2.59 | 0.3066 | 0.3066 | 1.50 | -- | -- | -- | -- | 265,361.00 | -- | 13.07 | -- | 15.20 | 66.19 | 64.10 | 20.36 | 19.79 | -- | -- | -- | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| Vetoquinol SA | 529.27m | 55.56m | 1.21bn | 2.48k | 21.72 | 2.29 | 14.99 | 2.29 | 4.70 | 4.70 | 44.73 | 44.53 | 0.7876 | 2.39 | 5.74 | 213,157.90 | 8.27 | 7.09 | 10.44 | 9.40 | 50.31 | 61.27 | 10.50 | 8.84 | 1.86 | -- | 0.0324 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| Cosmo Pharmaceuticals NV | 96.68m | 1.15m | 1.27bn | 325.00 | 1,016.72 | 2.72 | 81.39 | 13.13 | 0.0696 | 0.0696 | 5.86 | 25.99 | 0.1473 | 3.06 | 2.88 | 290,988.70 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Biotest AG | 782.60m | 176.90m | 1.36bn | 2.43k | 9.26 | 3.10 | -- | 1.74 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Fagron NV | 762.99m | 70.55m | 1.38bn | 3.46k | 19.47 | 2.96 | 12.77 | 1.81 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Genus plc | 791.01m | 39.25m | 1.40bn | 3.48k | 35.66 | 2.07 | 15.43 | 1.77 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
| Bonesupport Holding AB | 57.45m | 23.35m | 1.46bn | 121.00 | 62.89 | 29.54 | 60.34 | 25.50 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Evotec SE | 776.60m | -90.69m | 1.54bn | 5.06k | -- | 1.39 | -- | 1.98 | -0.5124 | -0.5124 | 4.39 | 6.24 | -- | -- | -- | 153,447.10 | -- | -0.0064 | -- | -0.0076 | 20.16 | 24.51 | -11.68 | -0.0178 | 1.79 | -2.09 | 0.3619 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BioArctic AB | 22.09m | -10.70m | 1.57bn | 90.00 | -- | 21.58 | -- | 70.85 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Galapagos NV | 293.40m | 30.71m | 1.70bn | 646.00 | 55.23 | 0.5859 | -- | 5.78 | 0.466 | 4.23 | 4.45 | 43.93 | 0.0653 | 0.1892 | 6.11 | 454,184.20 | 0.6829 | -1.48 | 0.7594 | -1.65 | 123.06 | -- | 10.47 | -14.42 | 9.70 | -- | 0.0028 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| Bavarian Nordic A/S | 890.95m | 132.05m | 1.94bn | 1.38k | 14.38 | 1.42 | 9.16 | 2.17 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Dermapharm Holding SE | 1.11bn | 56.58m | 1.98bn | 3.50k | 34.95 | 3.40 | 12.06 | 1.77 | 1.05 | 1.05 | 20.69 | 10.81 | 0.5137 | 1.25 | 9.68 | 318,823.00 | 2.51 | 8.68 | 3.01 | 10.06 | 63.32 | 61.94 | 4.89 | 12.31 | 0.7517 | 2.70 | 0.6367 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
Data as of May 31 2024. Currency figures normalised to Evotec SE's reporting currency: Euro EUR
